Skip to main content.

Weijing Sun, MD, FACP

Weijing Sun portrait
Professor, Medical Oncology

Professional Background

Weijing Sun, MD is currently the Sprint Professor of Medical Oncology; Professor of Medical Oncology and Cancer Biology; the Director of Medical Oncology Division, University of Kansas School of Medicine; and the Associate Director of University of Kansas Cancer Center.

He graduated from Shanghai Medical University (now mergied with Fudan University). He had his Internal Medicine residency training at Loyola University Medical Center, and Hematology-Oncology fellowship training at University of Pennsylvania. He served his assistant and associate professorship and had been the director of GI Medical Oncology at University of Pennsyvania until 2012. He then served his professorship, as the director of GI Medical Oncology and co-director of GI Cancer Research Exellency at the University of Pittsburgh until August, 2017 when he accepted the current position at the University of Kansas.

He is a national and international expert in gastrointestinal cancers. He is focusing on the treatment and clinical research of GI malignancies, mainly on the development of new drugs and biologic/targeted oriented agents in treatment/therapy (including translational and immune research) of GI cancers with great experiences in the early phase clinical trial (phase I, II) designing, protocol development and conduction, and many of these have been published. He has served as a member of ECOG-ACRIN GI core committee; a member of NCI GI Cancer’s Steering Committee Hepatobiliary Task Force. He has served as PI for many investigate initiated studies and pharmaceutical companies’ trials.

He has authored many publications including original clinical research articles, reviews, and invited editorial comments in a variety of peer-reviewed journals. He has also written chapters as a GI oncology expert for several medical textbooks including WebMD, Textbook of Gastroenterology. He is the editor-in-chief of the textbook of Multidisciplinary Therapy of GI Malignancies. He has had more than 130 publications. He is serving as a member of editorial boards or review committees for several professional journals. He serves as deputy editor-in-chief of Journal of Hematology andamp; Oncology; associated editor of Journal of Practical Oncology.

He served ASCO (American Society of Clinical Oncology) scientific program committee (both colorectal and non-colorectal cancer subcommittees); and currently is serving as the head of colorectal cancer education committee of the 2020 ASCO annual meeting. He serves as the activity director of ISGIO (International Society of Gastrointestinal Oncology), and recently elected as the president -elect of the organization. He served as the president and the board chair of CAHON (Chinses American Hematologist-Oncologist Network).

Education and Training
  • MD, Medicine, Shanghai Medical University (now called Fudan University), Shanghai, China
  • Other, Shanghai Medical University (now called Fudan University), Shanghai, China
  • Other, Immunology and Microbiology, University of Nebraska, Lincoln, NE
  • Other, University of Pennsylvania School of Medicine, Philadelphia, PA
  • Residency, Internal Medicine, Loyola University Medical Center, Maywood, IL
  • Clinical Fellowship, Hematology-Oncology, University of Pennsylvania, Philadelphia, PA
Licensure, Accreditations & Certifications
  • Medical Oncology, American Board of Internal Medicine
  • Kansas
  • Missouri



1) Focusing on clinical translational research in GI cancers, and in coolaberating with phase I therapeutic program in new drug especially targeted oriented and immunological agents in the treatment in colorectal, gastroesophageal, hepatobillary and pancreatic cancer.

2) Development of multidisciplinary combination therapy with radiation, surgical oncology, and interventional radiology in the treatment of upper GI cancers, hepatocellular carcinoma, and neuroendocrine neoplasm.

3) Conducting clinical studies by pass-way and anti-angiogenesis oriented agents based on the characteristics of hepatobiliary cancers (HCC, cholangiocarcinoma) as the new strategy.

4) Development in Neoadjuvant and adjuvant therapy in colorectal cancer, esophagiogastric and pancreatic Cancer.

5) International collaboration in molecular biology/pathology mechanism research and multidisciplinary treatment of esophagogastric cancer.

6) Mechanism correlation of immunotherapy and clinic outcome in GI cancers